ARTIVION INC (AORT)
Health Care · NYSE
Artivion is a leader in surgical solutions for aortic disease, combining proprietary stent grafts, mechanical heart valves, surgical sealants, and implantable tissue services.
What ARTIVION INC does
Artivion manufactures and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures, primarily for treating aortic disease. The company's core product lines include aortic stent grafts (both arch and abdominal), On-X mechanical heart valves, surgical sealants (BioGlue), and preservation services for implantable cardiac and vascular tissues. It operates through two segments: Medical Devices and Preservation Services, with a global footprint supported by subsidiaries including JOTEC in Germany and On-X Life Technologies in Texas.
Themes: ["Aortic disease treatment","Cardiac and vascular surgery","Stent graft systems","Mechanical heart valves","Surgical adhesives and sealants","Implantable tissues and biologics","Endovascular interventions","Tissue banking and preservation services"]
Fundamentals
- Price$24.11 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return-25.0% as of 2026-07-09 close
- P/E97.13 as of 2026-07-10
- Net margin+2.5% as of 2026-07-10
- Gross margin+64.5% as of 2026-07-10
- ROE+2.7% as of 2026-07-10
- Debt / equity0.49 as of 2026-07-10
- Revenue growth (YoY)+17.6% as of 2026-07-10
- Revenue CAGR (3y)+12.0% SEC XBRL
- Beta1.29 as of 2026-07-10
Key risks (from latest filing)
["Significant competition from larger well-capitalized competitors with greater financial resources, manufacturing efficiency, tissue processing capacity, and marketing capabilities that could render Artivion's products non-competitive or obsolete","Foreign exchange exposure from sales denominated in multiple currencies (Euros, Brazilian Reals, Polish Zlotys, British Pounds, Canadian Dollars, Swiss Francs) that materially impact revenue when translated to US Dollars","Regulatory approval and clearance risks for new products and expanded indications; competitors may obtain FDA or foreign regulatory approvals sooner, potentially delaying commercialization of Artivion's pipeline"]
Competitors & peers
- Medtronic (MDT)
- Boston Scientific (BSX)
- Cook Medical
- Terumo Aortic
- Cardinal Health
- LivaNova (LIVN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.